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Abstract 
The role of viral infections in adverse pregnancy outcomes has gained interest in recent 
years. Innate immune pattern recognition receptors (PRRs) and their signalling pathways that 
yield a cytokine output in response to pathogenic stimuli have been postulated to link 
infection at the maternal-fetal interface and adverse pregnancy outcomes. The objective of 
this study was to investigate the expression and functional response of nucleic acid ligand 
responsive Toll-like receptors (TLR3, 7, 8 and 9), and retinoic acid-inducible gene 1 (RIG-
I)-like receptors (RIG-I, MDA5 and LGP2) in human term gestation-associated tissues 
(placenta, choriodecidua and amnion) using an explant model. Immunohistochemistry 
revealed that these PRRs were expressed by the term placenta, choriodecidua and amnion. A 
statistically significant increase in interleukin (IL)-6 and/or IL-8 production in response to 
specific agonists for TLR3 (Poly(I:C); low and high molecular weight), TLR7 (Imiquimod), 
TLR8 (ssRNA40) and RIG-I/MDA5 (Poly(I:C)LyoVec) was observed; there was no 
response to a TLR9 (ODN21798) agonist. A hierarchical clustering approach was used to 
compare the response of each tissue type to the ligands studied and revealed that the placenta 
and choriodecidua generate a more similar IL-8 response, while the choriodecidua and 
amnion generate a more similar IL-6 response to nucleic acid ligands. These findings 
demonstrate that responsiveness via TLR3, TLR7, TLR8 and RIG-1/MDA5 is a broad 
feature of human term gestation-associated tissues with differential responses by tissue that 
might underpin adverse obstetric outcomes. 
 
 
  
Introduction 
Cytokine production at the materno-fetal interface is a part of normal pregnancy and the 
changes that occur with adverse obstetric outcomes might offer therapeutic targets 
1, 2
.  The 
relationship between bacterial infection and preterm rupture of the membranes (PROM) and 
preterm birth (PTB) has been given much attention 
3
 but recent years have seen the 
emergence of epidemiological evidence linking viral infection and adverse pregnancy 
4, 5
. 
These viral infections include human papillomavirus, hepatitis virus, herpes virus and 
cytomegalovirus which have been identified in both gestational tissues and amniotic fluid, 
and linked to increased risk of chorioamnionitis and spontaneous preterm birth 
6
. Therefore, 
better understanding of the response of gestation-associated tissues to viruses is required. 
 
Pattern recognition receptors (PRRs) are evolutionary conserved germline encoded receptors 
which recognise pathogen associated molecular patterns (PAMPs) from various 
microorganisms. Recognition of viral infections by the innate immune response occurs via 
nucleic acid responsive toll-like receptors (TLRs) 3, 7, 8 and 9, and retinoic acid-inducible 
gene (RIG)-1-like receptors (RLRs) RIG-I, MDA5 and LGP2 
7-10
. These receptors are 
located intracellularly where they are best positioned to encounter and respond to viruses 
11
. 
Better understanding of the expression and function of viral responsive PRRs at the materno-
fetal interface is required for our fundamental understanding of pregnancy immunology and 
for translating this to the development of new therapeutic approaches for adverse obstetric 
outcomes. There are no published studies of RLR expression in gestation-associated tissues. 
For TLRs 3, 7, 8 and 9 only the placenta has been investigated with transcripts and/or protein 
for all of these reported with functional responses observed to TLR3, TLR7 and TLR7/8 but 
not TLR9 agonists 
12
. Therefore, we investigated the expression and activity of nucleic acid 
ligand responsive TLRs (TLR3, 7, 8 and 9) and RLRs (RIG-I, MDA5 and LGP2) in human 
term placenta, choriodecidua and amnion using an explant model to better mimic the cellular 
heterogeneity that occurs in utero. A hierarchical clustering approach, as previously 
described for cytokine data 
13
, was implemented to better compare the response between 
different tissues and ligands. It is our hypothesis nucleic acid ligands will induce an 
inflammatory response in gestation associated tissues and that utilisation of hierarchical 
clustering to examine cytokine production by the placenta, choriodecidua and amnion in 
response to these PAMPs will highlight distinct differences in their responsiveness not 
revealed in previous studies. 
 
 
Materials and Methods 
Samples 
Placenta and fetal membrane samples were collected from healthy term newborns (>37 
weeks of gestation) delivered by ECS at Singleton Hospital, Swansea, UK. Written consent 
was obtained from all study participants following recruitment at the antenatal day 
assessment unit. Ethical approval for this study was given by Wales Research Ethics 
Committee 6 (REC No. 11/WA/0040).  
 
Explant Cultures 
Placenta. Placental explant cultures were prepared as described previously 
12
. The decidua 
basalis overlaying the maternal side of the placenta was removed and 1 cm
3
 pieces of 
placental tissue were extracted from various sites across the placenta, avoiding the fetal 
membranes, and placed into sterile calcium and magnesium free phosphate buffered saline 
(PBS; Life Technologies, UK). Tissue was washed repeatedly with PBS to remove 
contaminating blood. Tissue was then minced into smaller pieces and washed further. Pieces 
of tissue (1mm
3
 pieces to a total of 0.2 g) were transferred into the appropriate number of 
wells of a standard 12-well tissue culture plate (Greiner Bio-one, Germany) containing 1ml 
UltraCULTURE™ medium (Lonza, Switzerland), supplemented with 2 mM GlutaMAX™ 
(Life Technologies, UK) and 2 mM penicillin, streptomycin, fungisone (PSF; Life 
Technologies, UK).  
 
Membranes. Membranes were detached from the placenta. Choriodecidua and amnion were 
separated from each other by blunt dissection and placed individually and washed repeatedly 
in sterile Ca
2+ 
/ Mg
2+
 free phosphate buffered saline (PBS; Life Technologies) to remove 
blood. Explants were cut with an 8-mm biopsy punch (Stiefel): two discs of choriodecidua 
placed into 0.5ml Advanced RPMI supplemented with 2mM Glutamax, 2mM Penicillin 
streptomycin fungizone (PSF), 5mM 2-mercaptoethanol (2-ME; all Life Technologies) and 
2% fetal bovine serum (FBS; Hyclone) and 5mM 2-mercaptoethanol; and four discs of 
amnion placed into 0.5 ml Advanced DMEM (Life Technologies) supplemented with 2mM 
Glutamax, 2mM PSF and 2% FBS.  
 
Explant cultures were exposed to different stimuli; an unstimulated control was always 
included. Optimal levels of all agonists were determined by dose course studies on gestation-
associated tissues explants and the following final concentrations were used: Poly(I:C)LMW 
(TLR3, 25 μg/ml), Poly(I:C)HMW (TLR3, 25 μg/ml), Imiquimod (TLR7, 1 μg/ml) 
ssRNA40 (TLR8, 1 μg/ml), Poly(I:C)LyoVec (RIG-I/MDA5, 1 μg/ml) (all from Invivogen, 
USA), ODN21798 control or ODN21798 (TLR9, 1 µM; both Miltenyi Biotec, UK). All 
treatments were performed in duplicate. Cultures were incubated for 24 hours at 37°C in 5% 
CO2. Tissue free supernatants were collected by centrifugation for 7 minutes at 4°C, 515 x g 
and stored at -20°C for analysis using cytokine specific ELISAs. 
 
Cytokine production 
IL-6 and IL-8 in the tissue free supernatants of placenta, choriodecidua and amnion explant 
cultures collected after 24 h were measured using commercially available ELISA kits 
(DuoSet, R&D Systems) as per manufacturer’s instructions. 
 
Immunohistochemistry 
Immunohistochemistry was performed on formalin fixed, paraffin embedded sections (4 µm) 
of placenta and fetal membranes using the Ventana ULTRA automated staining instrument. 
The Optiview detection system was used without A/B blocker or amplification (except for 
anti-TLR9). Antigen retrieval was carried out in CC132 buffer for TLR3, RIG-I and MDA5 
and CC124 buffer for TLR7, TLR8 and LGP2. Primary antibodies, rabbit polyclonal anti-
TLR3 (5 µg/ml for 24 minutes), rabbit polyclonal anti-TLR7 (10 µg/ml for 36 minutes), 
rabbit polyclonal anti-TLR8 (5 µg/ml for 32 minutes), rabbit polyclonal anti-TLR9 (10 
µg/ml for 44 minutes), rabbit polyclonal anti-RIG-I (10 µg/ml for 32 minutes), rabbit 
polyclonal anti-MDA5 (5 µg/ml for 36 minutes), and rabbit polyclonal anti-LGP2 (5 µg/ml 
for 36 minutes) (all LifeSpan BioSciences, Inc, USA) were incubated at 36°C or, for anti-
TLR8, at room temperature. For control slides, primary antibody was replaced with 
polyclonal rabbit IgG (Biolegend) at a corresponding concentration. A tissue reported to 
express the receptor of interest was used for optimisation of staining and included as a 
positive control: tonsil (TLR3, TLR8, RIG-1, MDA5, LGP2), lung (TLR7), liver (TLR9). 
 
Data analysis 
All experiments were performed a minimum of three times. Cytokine production in untreated 
versus treated tissue was evaluated by paired two-tailed Student t-test or repeated measures 
one-way ANOVA with Dunnett’s multiple comparison test. A p-value of ≤ 0.05 was 
considered significant. Statistical significance was calculated using GraphPad Prism 
(Version 6, GraphPad Software Inc, USA). Heatmaps were constructed for each cytokine 
using the mean values generated by ELISA, corrected for baseline constitutive levels, with 
the 'heatmap.2' function in the 'gplots' R package 
14, 15
. Hierarchical clustering was performed 
using a ‘euclidean' distance method.  
 
 
 
 
 
 
 
 
 
Results 
Localization of TLR3, TLR7, TLR8 and TLR9 in human non-laboured gestation associated 
tissues 
Immunohistochemistry was used to determine which cells within the placenta and fetal 
membranes expressed TLR3, 7, 8 and 9 (Figure 1). In the placenta, expression of all four 
TLRs by trophoblast was a common feature with strong expression for both TLR3 and TLR8 
in the trophoblast and villous stromal cells. In the fetal membranes, amnion epithelial cells, 
chorionic trophoblasts and decidual cells all exhibited strong expression of TLR3 and TLR8. 
Expression of TLR7 was primarily localised to the chorion with weak staining in the amnion 
Intermittent expression of TLR9 was also observed.  
 
Functional response of term non-laboured gestation associated tissue to specific TLR3 
TLR7, TLR8 and TLR9 agonists 
TLR3. Functionality of TLR3, a receptor involved in the recognition of dsRNA, was 
investigated using a synthetic dsRNA analogue Poly(I:C) (Polyinosine-polycytidylic acid; 
both 25 µg/ml, n=9). Both a  high molecular weight (HMW, 1.5-8kb) and a low molecular 
weight (LMW, 0.2-1kb) version of the poly(I:C) were utilised based on reports of differences 
in activation efficacy determined by molecular weight 
16
. For the placenta and amnion, IL-8 
production was elevated significantly upon stimulation with both LMW and HMW Poly(I:C) 
whereas IL-6 was only elevated significantly upon stimulation with LWM Poly(I:C). For the 
choriodecidua HMW and LMW Poly(I:C) resulted in a significant increase of both IL-6 and 
IL-8 (Figure 2). HMW poly(I:C) gave a greater cytokine response than LMW poly(I:C) 
which was significant in all cases except for IL-6 production in the amnion.  
 
TLR7 and TLR8. TLR7 and TLR8 functionality were studied using imiquimod (R837) and 
ssRNA40/LyoVec each at 1 µg/ml (Figure 3; n=9). Imiquimod is small synthetic antiviral 
molecule in the imidazoquinoline family specific to TLR7, while ssRNA40/LyoVec, is a 
single stranded uridine-rich oligonucleotide derived from HIV-1 complexed with the 
transfection reagent LyoVec and is specific for TLR8 
17, 18
. The TLR8 agonist ssRNA40 
caused an increase in IL-6 and IL-8 in placenta, choriodecidua and amnion which was 
significant in all cases except for IL-8 in the amnion (Figure 3). In contrast, the TLR7 
agonist imiquimod induced a significant increase in IL-8 from all three tissues but only from 
the amnion for IL-6 (Figure 3).  
 
TLR9. The function of TLR9 was investigated using a synthetic P-class 
oligodeoxyribonucleotide containing unmethylated CpG motifs (ODN 221798) at 1 µM 
(Figure 4; n=7). A sequence control was also included. There was no significant effect of 
ODN221798 on either cytokine in any tissue. 
 
Localization of RIG-I, MDA5 and LGP2 in human non-laboured gestation associated tissues 
Immunohistochemistry was used to determine which cells within the placenta and fetal 
membranes expressed RIG-I, MDA5 and LGP2 (Figure 5). In the placenta, trophoblasts 
showed strong expression of all three RLRs with expression of MDA5 and LGP2 also in the 
villous stroma. In the fetal membranes, expression of RIG-I, MDA5 and LGP2 was observed 
on chorionic trophoblasts, decidual cells and amnion epithelial cells. 
 
Functional response of term non-laboured gestation associated tissue to a RIG-I/MDA5 
agonist 
RIG-I/MDA5 functionality was determined using Poly(I:C)/LyoVec, a complex between the 
transfection reagent LyoVec and HMW poly(I:C) at 1 µg/ml (Figure 6; n =9). Transfected 
Poly(I:C) is recognised by RIG-I/MDA5 unlike naked Poly(I:C) which is recognised by 
TLR3 
19, 20
. In all three tissues a significant increase in both IL-6 and IL-8 was observed in 
response to Poly(I:C)LyoVec.  
 
Hierarchical clustering of the response to nucleic acid sensing TLRs/RLRs 
Heatmaps were drawn to better visualise and enable a comparison of the cytokine response 
by each of the tissues and each of the ligands (Figure 7). Each row represents a tissue and 
each column represents a ligand with light grey representing high production levels and dark 
grey/black low.  Hierarchical clustering of the three tissues revealed that for IL-6 production 
the choriodecidua and amnion clustered together compared to the placenta whereas for IL-8 
production the placenta and choriodecidua clustered together compared to the amnion. When 
examining the response of the tissues to treatment with nucleic acid PAMPs two primary 
clusters for each cytokine were evident. For IL-6, the response of TLR3 activation by LMW 
poly(I:C) clustered with TLR8, independent of the TLR3/HMW poly(I:C), TLR7 and RIG-
I/MDA5. For IL-8, the response to TLR7/8 activation clustered independently of TLR3 (both 
LMW and HMW Poly(I:C)) and RIG-I/MDA5.  
 
 
 
Discussion 
This study reports for the first-time expression and function of RLRs by the placenta, 
choriodecidua and amnion. Additionally, we note distinct differences in TLR3, TLR7 and 
TLR8 function in these tissues compared to previous studies relating to the different agonists 
used. Furthermore, we provide a novel comparison of the cytokine producing capacity of the 
placenta, choriodecidua and amnion in response to nucleic acids. 
 
Protein expression of TLRs 3, 7, 8 and 9 was observed within placental trophoblast, amnion 
epithelium, chorionic trophoblasts and the decidua. There was variability in expression: most 
notably TLR9 showed lowest levels of staining and TLR7 expression was negligible within 
the decidua. Immunoreactivity  of TLR3, 7 and 8 has been reported previously in placental 
syncytiotrophoblasts and cytotrophoblasts of both normotensive and preeclampsia placentas 
21
. Our findings confirm this and extend this observation to the fetal membranes where 
immunoreactivity was also found. Broadly, patterns of immunoreactivity corresponded to the 
functional output apart from TLR9 where no functional output was observed.  
 
While a functional response to the TLR3 ligand poly(I:C) has been observed in both 
placental and fetal membrane explants, the efficiency of TLR3 activation has been reported 
to be influenced by the size of the dsRNA used 
16, 22
. Here we note TLR3 activation by LMW 
poly(I:C) induced a higher cytokine response than HMW poly(I:C) possibly due to better 
penetration into the cell of smaller RNAs. This highlights the importance of considering the 
size of poly(I:C) used when examining TLR3 function in gestational tissues, possibly 
offering an explanation for why no IL-8 production was observed in fetal membrane explants 
following poly(I:C) treatment 
6
. 
 
While TLR7 and TLR8 are phylogenetically related and both recognise ssRNAs, the 
cytokine response resulting from activation of TLR8 by both the placenta and fetal 
membranes is more robust than that of TLR7 apart from IL-8 production by the amnion. This 
might be related to the greater expression of TLR8 than TLR7 revealed by our 
immunohistochemical analysis. Previous functional investigations of TLR7 and TLR8 in 
gestational tissues have typically utilised dual synthetic agonists or ssRNAs 
6, 12
, noting both 
IL-6 and IL-8 production by the placenta 
12
 and IL-8 production by the fetal membranes 
6
 in 
response to treatment. These discrepancies likely reflect the model of investigation used, i.e. 
total fetal membrane explants 
6
 versus explants of choriodecidua and amnion as here. Tissue 
processing for ex vivo investigations can impact on cytokine measurements with punch 
biopsies of amnion or choriodecidua, as used here, typically making greater amounts of 
cytokines than dual compartment transwells 
23
. Furthermore, the activation of TLR7 and 
TLR8 by synthetic agonists results in differences in target cell selectivity and cytokine 
profile 
24
. 
  
We have previously reported that the human term placenta does not elicit either pro-
inflammatory (IL-6, IL-8 and TNFα) or anti-inflammatory (IL-10) cytokines in response to 
an A-class CpG ODN 
12
. However, several classes (A, B, C and P) of CpG ODN are 
available with C-class combining features of A-class and B-class, while P-class activates at a 
higher efficiency than C-class 
25, 26
. Therefore, we chose to use a P-class ODN for this study. 
Again, we report no functional response by any tissues to P-class CpG ODN despite TLR9 
immunoreactivity within placental trophoblasts and, more weakly, in various cells of the 
fetal membranes. To the best of our knowledge this is the first report of TLR9 protein 
localisation in the placenta and fetal membranes. Limited expression of TLR9 might offer an 
explanation as to why no functional response to CpG was observed corresponding to 
observations of expression versus function in monocytes and natural killer cells 
27
. However, 
measurement of a wider array of cytokines/chemokines could reveal TLR9 functionality. 
Increased MCP-1 and decreased G-CSF, IFNγ, MIP-1α, MIP-1β, RANTES and VEGF in 
response to Class-A CpG ODN by human fetal membrane explants has been reported 
28
. 
However, it is likely that TLR9 activity at the materno-fetal interface is tightly regulated 
rather than non-functional to minimise placental inflammation from endogenous signals. 
Hypomethylated fetal DNA, found in the placenta and maternal circulation with circulating 
levels increased in preeclampsia 
29
, can activate TLR9 signalling in human peripheral blood 
mononuclear cells (PBMCs) in vitro with elevated IL-6 production 
30
. Placental derived 
mitochondrial DNA is associated with TLR9 activation and vascular dysfunction in 
preeclampsia 
31
 and TLR9 expression is elevated on circulating plasmacytoid dendritic cells 
(pDCs) of preeclamptic versus healthy pregnant women and is accompanied by a lesser 
cytokine output in response to TLR9 activation 
32
.  
 
The cytoplasmic RNA helicases of the RLR family play a major role in host anti-viral 
defence. They detect viral RNA ligands in the cytoplasm, triggering activation of 
transcription factors and leading to production of type I IFNs and expression of other anti-
viral genes 
33
. Our knowledge of RLR expression and function in human gestation associates 
tissues is relatively limited. Here we demonstrate for the first-time immunoreactivity for 
RIG-I, MDA5 and LGP2 in the placenta and fetal membranes. Both RIG-I and MDA5 were 
localised to the placental trophoblasts, chorionic trophoblasts, decidual stromal cells and 
amnion epithelial cells. A corresponding functional output was observed with the dual 
agonist for these receptors. Further work is required to determine the relative contribution of 
RIG-I and MDA5 to this response. Recognition of dsRNAs by RIG-I and MDA5 is reported 
to be length dependent 
34
. As RIG-I selectively recognises short dsRNA and MDA5 long, 
given HMW dsRNA was used in our study the response is most likely MDA5-dependent but 
further work is required to confirm this. LGP2 shared its expression pattern with RIG-I and 
MDA5. This is not surprising given that LGP2 is a negative regulator of RLR signalling 
7
. 
This negative feedback takes place on many levels including competition for dsRNA, 
interaction with the adaptor molecule ISP-1, or direct binding of RIG-I 
35
. LGP2 regulatory 
function of RLR within gestation-associated tissues remains to be determined. 
 
Our investigation of the responsiveness of gestation-associated tissues to nucleic acid PRRs, 
namely TLR3, 7, 8 and 9, and RIG-I and MDA5 provides further insight into inflammatory 
responses at the materno-fetal interface. Protein expression of these PRRs and LGP2 was a 
broad feature of human term gestation-associated tissues yet there were subtle differences in 
functional responses. Hierarchical clustering enabled elucidation of these key differences 
between tissues and treatments to be highlighted. This approach revealed that the placenta 
and choriodecidua respond to nucleic acid ligands more similarly than the amnion regarding 
the production of IL-8. IL-8 is a key chemokine in the recruitment and activation of 
neutrophils 
36
 which have a role in anti-viral immunity 
37
. Neutrophil infiltration of both the 
placenta and decidua occurs during bacterial infection 
38, 39
 and this might also be the case 
during viral infection. In contrast, hierarchical clustering revealed that in the regards to IL-6 
production, the choriodecidua and amnion share a greater functional similarity.  
 
The clustering approach utilised here has highlighted some key differences between tissues 
in relation to their responsiveness to nucleic acids PAMPs but this has limitations. This is a 
study of heterogeneous tissue explants so the relative numbers of responsive cells in each of 
the tissues will differ. This is evident by the constitutive production of both cytokines by 
each tissue and we have corrected all comparisons for this. However, normalisation of 
cytokine production to total protein content prior to baseline corrections would form the 
basis of future investigations. Furthermore, we have only applied this approach to the 
production of IL-6 and IL-8, based on the expectation that these would most likely yield 
responses to viral ligands 
40, 41
 and have been implicated in anti-viral defence 
42
. While these 
are key cytokines in the physiology and pathophysiology of labour, other cytokines including 
IL-1β, IL-10 and TNFα have also been implicated (2). Therefore, an extensive examination 
of other pro- and anti-inflammatory cytokine perhaps after multiplex analysis would provide 
a more detailed insight into the inflammatory response of gestational tissues. 
 
While the focuses of this study has been TLRs and RLRs, other nucleic acid sensing innate 
immune receptors have been described, namely the cytosolic DNA sensors (CDS), 
alternatively known as the absent in melanoma 2 (AIM2)-like receptors (ALRs) 
43
. Several 
CDS have been described including DAI, LRRFIPI, IFI16, DDX41, cGAS and AIM2. To 
date, little is known about either the expression or function of these cytosolic DNA sensors 
in gestational tissues apart from IFI16, which is associated with non-necroptotic 
programmed cell death of human trophoblasts following dsDNA exposure 
44
. Furthermore, 
placenta expression of IFI16 is significantly elevated in women with preeclampsia and this 
can be mimicked in vitro by treating placental trophoblasts with poly(dA:dT) 
45
. This 
implicates IFI16 and possibly other CDS and the DNA sensing receptors studied herein in 
preeclampsia and highlights the importance of understanding the potential dysfunction of 
these receptors and their signalling pathways in pregnancy. 
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Figure 1. Immunolocalisation of nucleic acid sensing TLRs in human gestation associated 
tissues. Negative (isotype match) and positive (TLR3 & TLR8 – tonsil; TLR7 – lung; TLR9 
- liver) controls are also shown. A representative example of 7 is shown. Original 
magnification x40. 
 
Figure 2. TLR3 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion. IL-6 and IL-8 production (ng/ml ± SEM) by the (A-B) placenta, 
(C-D) choriodecidua (E-F) amnion following stimulation with Poly(I:C)LMW and 
Poly(I:C)HMW (both 25 µg/ml; n=9). Statistically significant differences compared to 
unstimulated control are shown: * p< 0.05, ** p<0.01. 
 
Figure 3. TLR7 and TLR8 agonist induced cytokine response by the term non-laboured 
placenta, choriodecidua and amnion. IL-6 and IL-8 production (ng/ml ± SEM) by the (A-B) 
placenta, (C-D) choriodecidua, and (E-F) amnion following stimulation with imiquimod 
(TLR7) and ssRNA40/LyoVec (TLR8) (both 1 µg/ml; n=9).  Statistically significant 
differences compared to unstimulated control are shown: * p< 0.05, ** p<0.01, *** p< 
0.001. 
 
Figure 4. TLR9 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion. IL-6 and IL-8 production (ng/ml ± SEM) by the (A-B) placenta, 
(C-D) choriodecidua, and (E-F) amnion following stimulation with ODN21798 control or 
ODN21798 (both 1 μM; n=7). No statistically significant differences were observed. 
 
Figure 5. Immunolocalisation of RLRs in human gestation associated tissues. Negative 
(isotype match) and positive (all tonsil) controls are also displayed. A representative example 
of 7 is shown. Original magnification x40. 
 
Figure 6. RIG-1/MDA-5 agonist induced cytokine response by the term non-laboured 
placenta, choriodecidua and amnion. IL-6 and IL-8 production (ng/ml ± SEM) by the (A-B) 
placenta, (C-D) choriodecidua, and (E-F) amnion in response to Poly(I:C)LyoVec (1 µg/ml; 
n=9). Statistically significant differences compared to unstimulated control are shown: * p< 
0.05, ** p<0.01. 
 
Figure 7. Comparison of nucleic acid induced cytokine production by the placenta, 
choriodecidua and amnion. Heatmap generated using the mean levels of (A) IL-6 and (B) IL-
8 production as measured by ELISA, the production level was standardised by correction for 
background levels of cytokine from unstimulated tissues. Greyscale is used with white 
signifying highest production and black lowest. Hierarchical clustering was performed on 
both the rows (by tissue) and columns (by receptor).  
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